Discontinued — last reported Q4 '25
Natera, Inc. Single Reportable — Gross Profit increased by 15.9% to $445.43M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 48.7%, from $299.64M to $445.43M. Over 3 years (FY 2022 to FY 2025), Single Reportable — Gross Profit shows an upward trend with a 60.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests improved operational efficiency or higher pricing power, whereas a decrease may indicate rising input costs or pricing pressure in the diagnostic market.
Gross profit represents the revenue remaining after deducting the direct costs associated with providing diagnostic test...
Standard gross profit metric used across the healthcare and diagnostics industry to assess core operational performance.
ntra_segment_single_reportable_gross_profit| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $90.99M | $90.99M | $90.99M | $90.99M | $123.19M | $123.19M | $123.19M | $123.19M | $208.60M | $243.17M | $271.75M | $299.64M | $316.77M | $346.60M | $384.38M | $445.43M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +35.4% | +0.0% | +0.0% | +0.0% | +69.3% | +16.6% | +11.8% | +10.3% | +5.7% | +9.4% | +10.9% | +15.9% |
| YoY Change | — | — | — | — | +35.4% | +35.4% | +35.4% | +35.4% | +69.3% | +97.4% | +120.6% | +143.2% | +51.9% | +42.5% | +41.4% | +48.7% |